Drugs / Ortuzumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04915482 | Jun 2021 → Jan 2025 | Evans syndrome, connective tissue disorder | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05718856 | Feb 2023 → May 2025 | primary thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ortuzumab | “Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a...” NCT04915482 ↗1“Two kinds of anti-CD 20 monoclonal antibody could be used in this study, including Rituximab and Ortuzumab.” NCT05718856 ↗ |
| Modality | Monoclonal antibody | “Two kinds of anti-CD 20 monoclonal antibody could be used in this study, including Rituximab and Ortuzumab.” NCT05718856 ↗ |